A fter myocardial infarction (MI), the heart undergoes a remodeling process characterized by significant hypertrophy of the noninfarcted myocardium. [1] [2] [3] [4] The process is adaptive in nature and primarily represents a universal response of the heart to systolic or diastolic overload from whatever cause. After a stage of compensated hypertrophy, heart failure may ensue. Heart failure is characteristically associated with systolic and diastolic dysfunction. The contraction duration is prolonged, and relaxation abnormalities occur in patients with heart failure. 5, 6 These changes are accompanied by prolonged [Ca 2ϩ ] i transients in isolated ventricular myocytes from failing hearts. 6, 7 The prolonged diastolic decay of the transient in heart failure is most probably a result of reduced Ca 2ϩ uptake or storage by the sarcoplasmic reticulum (SR). 8 At present the biochemical mechanisms for this defect are controversial.
The SR plays a critical role in the regulation of cytosolic Ca 2ϩ concentrations and thus, excitation-contraction coupling in adult myocardium. The release and reuptake of Ca 2ϩ by the SR is tightly regulated in mammalian heart and is critical for systolic and diastolic function. Contraction is mediated through the release of Ca 2ϩ from the SR, whereas relaxation involves the active reuptake of Ca 2ϩ into the SR lumen by SR Ca 2ϩ -ATPase (SERCA2). In cardiac muscle, SERCA2 is under reversible regulation by phospholamban (PLB). Dephosphorylated PLB inhibits the affinity of the SERCA2 for Ca 2ϩ and phosphorylation relieves the inhibitory effects. 9, 10 The mRNA levels for PLB and SERCA2 have been reported to be reduced in failing human [11] [12] [13] and rat 14 hearts. However, controversy exists regarding the corresponding protein levels. [15] [16] [17] [18] [19] It is conceivable that the abnormality could be caused by functional alterations in PLB and SERCA2 in the failing ventricle without changes in their protein levels. A reduced uptake of Ca 2ϩ into SR as well as reduced release from SR could result entirely from reduced phosphorylation of PLB.
There is significant interest in understanding the nature of alterations associated with the remodeling process and the transition from an adaptive compensated hypertrophy to a decompensated failing heart. Three weeks after MI in the rat, remodeled hypertrophy of noninfarcted myocardium is at its maximum, and the heart is in a compensated stage with no evidence of heart failure. 20 However, some studies have shown that the left ventricular end-diastolic pressure may be increased and both ϩdP/dt and -dP/dt could be depressed at this stage. 20 Systolic [Ca 2ϩ ] i also was shown to be slightly but significantly lower and diastolic [Ca 2ϩ ] i higher in post-MI myocytes. 21 The molecular and biochemical bases of these alterations are not known. The present study was designed to investigate possible defects in the ␤-adrenergic receptor-G s/i protein-adenylyl cyclase-cAMP-protein kinase A (PKA)-phosphatase pathway as well as molecular or functional alterations of SERCA2 and PLB at the stage of compensated hypertrophy of the post-MI rat heart. These data may provide insight into the nature of early alterations associated with the attempt of the heart to adapt to an increased workload and the possible negative consequences of some of these adaptive mechanisms.
Materials and Methods

Materials
Anti-G ␣s and -G ␣i polyclonal antibodies were from Santa Cruz Biotechnology. Anti-SERCA2 monoclonal antibody was from Affinity Bioreagents, Inc. The polyclonal antibodies PS-16 and PT-17 and monoclonal antibody A1 were obtained from PhosphoProtein Research.
Experimental Model
Sprague-Dawley rats weighing 200 to 250 g underwent either coronary ligation or sham operation as previously described. 22 The rats were studied 3 weeks after operation. Measurements were made for heart rate; systolic, diastolic, and mean systemic pressure; and left ventricular end-diastolic pressure (LVEDP), and the maximal dP/dt was determined by averaging 10 consecutive cycles.
Preparation of Isolated Cardiac Myocytes
Ventricular myocytes from adult rats were isolated by collagenase digestion as described previously. 22 Some of the freshly isolated myocytes from sham and post-MI rats were preincubated with the phosphodiesterase (PDE) inhibitor Ro-20-1724 (0.7 mmol/L) alone or plus isoproterenol (50 nmol/L) or forskolin (1 mol/L) for 10 minutes at room temperature, with 1 g/mL pertussis toxin (PTX) for 3 hours at 37°C and with 0.5 mol/L okadaic acid (OA) for 30 minutes at room temperature.
Radioligand Binding Assay
Cell surface ␤-adrenergic receptors were quantified as previously described. [23] [24] [25] 
cAMP Determination
The procedure for extraction of cAMP from myocyte suspensions and cAMP quantitative enzyme immunoassay kit (EIA system) were provided by Amersham Life Science.
Western Blot Analysis
Myocyte suspensions were briefly spun down, and the pellets were solubilized in 2ϫ Laemmli buffer. 26 Protein concentration was determined according to Bradford. 27 Immunoblot detection was accomplished by following the manufacturer's instructions (Tropix, Inc, or NEB Labs, Inc).
Preparation of RNA From Ventricular Muscle
Total RNA was extracted from left ventricle using standard protocol. 28 
Construction of DNA Templates
DNA templates were prepared by subcloning cDNA fragments into pCRII (Invitrogen). The cDNA fragments were prepared by reverse transcriptase-polymerase chain reaction from total cellular RNA isolated from normal rat heart. For each template, the following sequences were used as primers: PLB 320 bp (nucleotides 21 to 340 29 ) forward, GTCTGCATTGTGACGATCAC, and reverse, AGGTCTGCGGTGGCGACAGC, and SERCA2 260 bp (nucleotides 2281 to 2540 30 ) forward, TCCTTTGATGAGATCACAGC, and reverse, GCCGTCAGGAAGATACAGAC. Internal control used was a cDNA fragment of cyclophilin 31 (nucleotides 38 to 142) from Ambion.
RNase Protection Assay
RNase protection assays were performed as previously described. 32 
Preparation of Left Ventricular Membrane Vesicles
Membrane vesicles were prepared as described by Neumann et al. 33 
Protein Phosphatase Activity Assay
Assays were performed by using manufacturer's protocol (protein phosphatase assay system, Life Technologies). Phosphatase activity was measured at 30°C using 32 P-labeled phosphorylase a as substrate.
Tricholoroacetic Acid (TCA) Extraction and Assay of Phosphatase Inhibitor Activity
TCA extract enriched in phosphatase inhibitors 1 and 2 was isolated from left ventricular myocardium, and the phosphatase inhibitor activity in extracts was measured as described by Ahmad et al. 34 Measurement of [Ca 2؉ ] i Transient [Ca 2ϩ ] i transient in myocytes from sham and post-MI rats was measured as described by Spurgeon et al. 35 The sampling rate was 5 milliseconds. Data were not filtered.
Statistical Analysis
Data are expressed as meanϮSEM. Comparisons between sham and post-MI myocardium were performed by Student nonpaired t test. A value of PϽ0.05 was accepted as statistically significant.
An expanded Materials and Methods section is available online at http://www.circresaha.org.
Results
Hemodynamic Characterization
Hemodynamic measurements were taken before the heart was removed. There was no significant difference between sham and post-MI rats regarding heart rate (sham, 319Ϯ20 bpm; post-MI, 325Ϯ18 bpm), systolic blood pressure (sham, 115Ϯ12 mm Hg; post-MI, 112Ϯ10 mm Hg), and mean sys- 
␤-Adrenergic Receptor Density
To determine whether changes of ␤-adrenergic receptor density occur in isolated 3-week-post-MI myocytes, receptor binding assays were performed. Cell-surface ␤-adrenergic receptors were quantified using the hydrophilic ligand [
3 H]CGP-12177, which specifically labels cell-surface receptors. 23 The binding data from 5 sham and 5 post-MI rat hearts were analyzed with a nonlinear least-squares method. The ␤-adrenergic receptor density was significantly increased from 13.6Ϯ0.3 to 20.6Ϯ0.7 fmol/10 5 cells (PϽ0.05) in sham (nϭ8) and post-MI (nϭ8) myocytes, respectively. However, the ␤-adrenergic receptor densities normalized to protein concentrations showed no significant change between sham and post-MI myocytes (14.0Ϯ0.6 fmol/mg sham versus 13.6Ϯ0.9 fmol/mg post-MI; NS). The affinity (K d ) of the receptor for the radioligand in the myocytes was also not affected after MI (41.2Ϯ2.3 pmol sham versus 38.9Ϯ2.1 pmol post-MI; NS). Figure 1 shows results of Western blot analysis of G ␣i and G ␣s protein levels. Compared with sham, G ␣i immunoreactivity was significantly increased by 55% (PϽ0.03, nϭ8), whereas G ␣s protein level was found unchanged in 3-week-post-MI myocytes.
G ␣i and G ␣s Protein Densities
Adenylyl Cyclase Activity
The cAMP EIA system was used to measure the cAMP contents in myocytes with or without stimulation. The basal activity of adenylyl cyclase was unmodified, being 4.2Ϯ0. Figure 5 compares the level of phosphorylated PLB and total PLB in sham and post-MI myocytes. The antibody p-16 that recognizes phosphorylated Ser16 in PLB, which is known to be the main phosphorylation site by PKA, was used. After a second antibody and luminescent detection, the membrane was stripped and relabeled with antibody A1, which recognizes total PLB ( Figure 5A ). There was no change in the level of total PLB, but there was a 76% (PϽ0.05, nϭ6) decrease in the basal level of p16-PLB in post-MI myocytes. The level of p16-PLB was only slightly corrected by Ro-20-1724 alone. However, the addition of forskolin or isoproterenol increased the p16-PLB in post-MI to the same level as sham ( Figure  5B ). Similarly, the basal level of p17-PLB was also found to be significantly decreased (51%, PϽ0.05) in post-MI (nϭ6) compared with sham myocytes (nϭ6), and the addition of forskolin or isoproterenol increased the p17-PLB level in post-MI to the same level as in sham ( Figure 6 ). Taken together, these results further support the intact function in dissociated myocytes.
PLB and SERCA2 mRNAs Levels
PLB and SERCA2 Protein Levels
PLB Phosphorylation
Phosphatase Activities
Activators of phosphatases can dephosphorylate PLB and exert a negative inotropic effect. 36 Type 1 and 2A phosphatases are the main phosphatases of the myocardium, 37 and both phosphatases can dephosphorylate PLB. 38 We, therefore, compared phosphatase 1 and 2A activities in membrane vesicle preparations from sham and post-MI rat left ventricles. Figure 7A shows the results of assays of protein phosphatase activities using radiolabeled phosphorylase a as substrate. Types 1 and 2A were differentiated in the presence of 10 nmol/L OA. 39 The type 1 phosphatase activity was significantly increased by 32% in post-MI compared with sham myocytes (PϽ0.05, nϭ6), and there was no change in the type 2A phosphatase activity ( Figure 7A ). Figure 7B demonstrates that the acid extract enriched in phosphatase inhibitors 1 and 2 showed no difference in inhibition of purified phosphatase 1 activity.
Effects of G i Protein, PDE, and Protein Phosphatase on Phosphorylation of PLB
We used PTX, Ro-20-1724, and 0.5 mol/L OA to block G i protein, PDE, and protein phosphatase activities, respectively, to study their effects on the levels of p16-PLB and p17-PLB in 3-week-post-MI myocytes. The results of these experiments are illustrated in Figures 8 and 9 . In Figure 8 , OA alone or in combination with Ro-20-1724 significantly increased the level of p16-PLB in post-MI myocytes by 2.3 to 8.4 times the basal level (PϽ0.05, nϭ6), respectively. Lesser changes were seen with PTX alone or PTX plus Ro-20-1724. Figure 9 shows that OA alone as well as in combination with Ro-20-1724 significantly increased the p17-PLB in post-MI myocytes by 10 times. Lesser effects were also seen with PTX plus Ro-20-1724. No significant changes were found in both p16-and p17-PLB levels when a low dose of OA (10 nmol/L) was used (data not shown).
[Ca 2؉ ] i Transient in Sham and Post-MI Myocytes
We further compared the changes of [Ca 2ϩ ] i transient in sham and post-MI myocytes before and after incubation with 10 nmol/L and 0.5 mol/L of OA. Figure 10 shows transients recorded from a sham and a post-MI myocyte before and after incubation with OA. Data from 6 sham (nϭ17 cells) and 6 post-MI (nϭ24 cells) myocyte preparations are summarized in 
Discussion
Three weeks after MI, the heart is in a compensated stage with remodeled hypertrophy of noninfarcted myocardium. However, abnormalities of the diastolic function could be detected in vivo as increased LVEDP 20 and in vitro as an increased diastolic [Ca 2ϩ ] i . 21 Our findings of prolonged relaxation of the Ca 2ϩ transient in post-MI remodeled myocytes is consistent with those observations and suggest a reduced SERCA2 activity. 12 We have shown that the reduction in SERCA2 activity at this stage was not a result of altered gene expression and protein levels of SERCA2 and its regulatory protein PLB, but it was a result of decreased basal levels of both p16-PLB and p17-PLB. A recent study has shown that phosphorylation of Ser16 is a prerequisite for Thr17 phosphorylation in PLB, and prevention of phosphoserine formation results in attenuation of the ␤-agonist stimulatory responses in the mammalian heart. 40 Reduced p-PLBs are expected to increase the inhibitory effect of PLB on SERCA2. In principle, the reduction in p-PLBs can result either from a diminished cAMP content or an increased activity of protein phosphatases. We have shown that the reduced p-PLBs were not caused by significant abnormalities of the ␤-adrenergic receptor-G protein-adenylyl cyclasecAMP-PKA complex, because stimulation of ␤-adrenergic receptor, G s protein, or adenylyl cyclase could increase the level of p-PLBs in post-MI myocytes to the same level as in sham myocytes. Further, no changes were found in the ␤-adrenergic receptor density, G s␣ protein expression level, and adenylyl cyclase activity. Our findings that G i protein level was significantly increased in 3-week-post-MI myocardium and that PTX, in combination with Ro-20-1724, can slightly but significantly increase the PLB phosphorylation levels indicated that an increased G i level may play a role in post-MI hypertrophied myocardium. G i protein was found to be increased in rat heart as early as 4 weeks after MI, 41 in pacing-induced heart failure in dogs, 42 and in human heart failure. 43 An increased G i protein level could alter activity of the catalytic subunit of adenylyl cyclase and result in an increased level of inhibition of adenylyl cyclase activity. Further, G i protein stimulation could enhance phosphatase activity via inhibitor-1. 44, 45 Our results seem to support the latter mechanism, given that we found no change in adenylyl cyclase activity in post-MI compared with sham myocytes. However, the slight but significant increase of p-PLB levels in post-MI myocytes after incubating with PTX suggests that, besides G i protein alteration, additional defects exist in post-MI myocytes.
Our results strongly suggest that the decreased basal p16-PLB and p17-PLB levels in our animal model were mainly a result of the enhanced activity of type 1 phosphatase that dephosphorylates p16-PLB and p17-PLB. Type 1 phosphatase has been reported to be capable of dephosphorylating membrane-associated PLB when it is phosphorylated by PKA. 38, 46, 47 Further evidence that supports this hypothesis is our finding that 0.5 mol/L of OA, a protein phosphatase inhibitor, dramatically increased p16-PLB as well as p17-PLB levels in post-MI myocytes. This is one more indication that the PLB phosphorylation process in compensated post-MI myocardium is essentially normal. The same dose of OA also partially corrected the prolonged relaxation of the Ca 2ϩ transient. However, PLB is only one of the phosphoproteins contributing to the accelerated relaxation of the Ca 2ϩ transient.
It is important to emphasize the advantage of the use of dissociated myocytes rather than myocardial homogenates in the study of the ␤-adrenergic receptor-G s/i protein-adenylyl cyclase-cAMP-PKA pathway in the post-MI remodeled hypertrophied myocardium. Tissue homogenates inevitably include other cell types besides myocytes. This is especially important when comparing normal and diseased myocardium, because nonmyocyte structures are also altered after MI. 48 Further, using hydrophilic radioactive probe in ␤-adrenergic receptor binding assays on isolated myocytes would allow the quantification of receptor density exclusively on the extracellular membrane of intact cell, an effective approach to compare diseased and normal myocardium. 24 The role of PLB in the regulation of basal myocardial contractility has been recently elucidated through the generation of a PLB-deficient mouse model. 49 Ablation of PLB was associated with a significant increase in intraventricular pressure and in the rates of contraction and relaxation, assessed in isolated work-performing heart preparations. 49 The elevated contractile parameters in PLB-deficient hearts could not be further stimulated with isoproterenol. 49 These findings demonstrated that PLB is a repressor of left ventricular basal contractile parameters, and alterations in the levels of PLB would be expected to result in alterations in myocardial contractility. The rates of phosphorylation/dephosphorylation reactions on PLB appear to be faster than those of other phosphoproteins. PLB has been shown to be phosphorylated in vivo, and the resulting stimulatory effects on SR Ca 
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the ␤-adrenergic responses in the mammalian heart. 50 -52 The function of PLB during catecholamine stimulation of the heart suggests a role for this protein as an internal "brake mechanism." 53 Ser16 of PLB is the first and main site to be phosphorylated in response to an increase in cAMP levels during ␤-agonist administration, followed by an increase in the activity of the cardiac SR Ca 2ϩ transport system and increased rate of cardiac relaxation. 51, 54, 55 In addition to phosphorylation of PLB, myocardial SR possesses phosphatase activity capable of dephosphorylating PLB. SR-associated "PLB phosphatase" has been shown to be inhibited by inhibitor-1, 46 which is very similar to protein phosphatase 1. 38, 46 In addition to activation of PKA through augmentation of cAMP, ␤-agonist may also exert its effect on augmenting cardiac contractility by phosphorylation of protein phosphatase inhibitor-1. 56 A decrease in type 1 protein phosphatase activity through phosphorylation of phosphatase inhibitor-1 is expected to further augment the effects of ␤-agonist. Our findings that isoproterenol and forskolin can increase both p16-PLB and p17-PLB levels in post-MI myocytes to the same levels in sham could be explained by their inhibitory effects on phosphatases by phosphorylating protein phosphatase inhibitor-1.
In summary, the present study has shown that alterations in diastolic function develop much earlier in the post-MI remodeled rat heart and well before the onset of overt heart failure. The prolonged relaxation of post-MI remodeled myocytes was due to decreased basal levels of both p16-and p17-PLB. The latter could be explained, in part, by increased type 1 protein phosphatase activity. However, other factors, including increase of G i , could also be involved.
